Drugs / GSK3003891A
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03191383 | Jul 2017 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 2 | NCT02956837 | Nov 2016 → Aug 2017 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02753413 | Apr → Jun 2016 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3003891A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03191383 ↗ |
| Modality | Vaccine | “1 dose of RSV-prefusion F protein (PreF) vaccine” PMID 29401325 ↗ Apr 2018 |
| Route | Intramuscular | “Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.” NCT02753413 ↗ |